Taro Pharmaceutical Industries Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $37.62
- Today's High:
- $38.37
- Open Price:
- $38
- 52W Low:
- $22.89
- 52W High:
- $42.22
- Prev. Close:
- $38.13
- Volume:
- 16441
Company Statistics
- Market Cap.:
- $1.43 billion
- Book Value:
- 46.256
- Revenue TTM:
- $575.18 million
- Operating Margin TTM:
- 0.35%
- Gross Profit TTM:
- $293.14 million
- Profit Margin:
- 3.72%
- Return on Assets TTM:
- 0.06%
- Return on Equity TTM:
- 1.24%
Company Profile
Taro Pharmaceutical Industries Ltd had its IPO on 1993-04-01 under the ticker symbol TARO.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Taro Pharmaceutical Industries Ltd has a staff strength of 1,554 employees.
Stock update
Shares of Taro Pharmaceutical Industries Ltd opened at $38 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $37.62 - $38.37, and closed at $38.27.
This is a +0.37% increase from the previous day's closing price.
A total volume of 16,441 shares were traded at the close of the day’s session.
In the last one week, shares of Taro Pharmaceutical Industries Ltd have slipped by -4.13%.
Taro Pharmaceutical Industries Ltd's Key Ratios
Taro Pharmaceutical Industries Ltd has a market cap of $1.43 billion, indicating a price to book ratio of 0.7446 and a price to sales ratio of 1.9102.
In the last 12-months Taro Pharmaceutical Industries Ltd’s revenue was $575.18 million with a gross profit of $293.14 million and an EBITDA of $35.06 million. The EBITDA ratio measures Taro Pharmaceutical Industries Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Taro Pharmaceutical Industries Ltd’s operating margin was 0.35% while its return on assets stood at 0.06% with a return of equity of 1.24%.
In Q2, Taro Pharmaceutical Industries Ltd’s quarterly earnings growth was a negative -28.7% while revenue growth was a positive 1.4%.
Taro Pharmaceutical Industries Ltd’s PE and PEG Ratio
- Forward PE
- 9.8135
- Trailing PE
- 65.7414
- PEG
- 0
Its diluted EPS in the last 12-months stands at $0.58 per share while it has a forward price to earnings multiple of 9.8135 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Taro Pharmaceutical Industries Ltd’s profitability.
Taro Pharmaceutical Industries Ltd stock is trading at a EV to sales ratio of 0.8013 and a EV to EBITDA ratio of 5.7714. Its price to sales ratio in the trailing 12-months stood at 1.9102.
Taro Pharmaceutical Industries Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $2.14 billion
- Total Liabilities
- $385.01 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $6.84 million
- Dividend Payout Ratio
- 0%
Taro Pharmaceutical Industries Ltd ended 2024 with $2.14 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.14 billion while shareholder equity stood at $1.74 billion.
Taro Pharmaceutical Industries Ltd ended 2024 with $0 in deferred long-term liabilities, $385.01 million in other current liabilities, in common stock, $0 in retained earnings and $17.23 million in goodwill. Its cash balance stood at $124.17 million and cash and short-term investments were $806.15 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Taro Pharmaceutical Industries Ltd’s total current assets stands at $1.29 billion while long-term investments were $451.17 million and short-term investments were $681.99 million. Its net receivables were $283.43 million compared to accounts payable of $59.37 million and inventory worth $204.59 million.
In 2024, Taro Pharmaceutical Industries Ltd's operating cash flow was $0 while its capital expenditure stood at $6.84 million.
Comparatively, Taro Pharmaceutical Industries Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $38.27
- 52-Week High
- $42.22
- 52-Week Low
- $22.89
- Analyst Target Price
- $35
Taro Pharmaceutical Industries Ltd stock is currently trading at $38.27 per share. It touched a 52-week high of $42.22 and a 52-week low of $42.22. Analysts tracking the stock have a 12-month average target price of $35.
Its 50-day moving average was $37.38 and 200-day moving average was $31.93 The short ratio stood at 5.2 indicating a short percent outstanding of 0%.
Around 7848.4% of the company’s stock are held by insiders while 1216.3% are held by institutions.
Frequently Asked Questions About Taro Pharmaceutical Industries Ltd
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.